Nicoya, a biotechnology company, completed the acquisition of LSK Technologies, a decentralizing laboratory testing with their high-throughput lab-in-a-box platform. Financial terms were not disclosed. “This acquisition comes as a natural progression for both organizations as we simultaneously look to disrupt the molecular detection and diagnostics space with our next-generation technologies. Joining forces with LSK presents a game-changing opportunity to strengthen our foundation in point-of-need testing and vastly change the future of how we discover and test for diseases. We are excited to bring the team on board and combine our unique expertise to expand Nicoya’s technology portfolio," Ryan Denomme, Nicoya CEO and Co-Founder.